Related references
Note: Only part of the references are listed.MALDI imaging facilitates new topical drug development process by determining quantitative skin distribution profiles
David Bonnel et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2018)
Autoimmunity and COPD Clinical Implications
Gaetano Caramori et al.
CHEST (2018)
Role of efflux transporters in the absorption, distribution and elimination in rodents of a novel PDE4 inhibitor, CHF6001
V. Cenacchi et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
Topical application of anthranilate derivatives ameliorates psoriatic inflammation in a mouse model by inhibiting keratinocyte-derived chemokine expression and neutrophil infiltration
Zih-Chan Lin et al.
FASEB JOURNAL (2018)
Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation
Samar H. Ibrahim et al.
GUT (2018)
Roflumilast, type 4 phosphodiesterase inhibitor, attenuates inflammation in rats with ulcerative colitis via down-regulation of iNOS and elevation of cAMP
Nahla E. El-Ashmawy et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Inhibition of Phosphodiesterase 4 by FCPR03 Alleviates Lipopolysaccharide-Induced Depressive-Like Behaviors in Mice: Involvement of p38 and JNK Signaling Pathways
Hui Yu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Effect of roflumilast on chronic obstructive pulmonary disease: a systematic review and meta-analysis
Lu-Fei Shen et al.
IRISH JOURNAL OF MEDICAL SCIENCE (2018)
Phosphodiesterase 4 inhibitors
Rema Zebda et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
A negative allosteric modulator of PDE4D enhances learning after traumatic brain injury
David J. Titus et al.
NEUROBIOLOGY OF LEARNING AND MEMORY (2018)
The relationship between inflammation and remodeling in childhood asthma: A systematic review
Jose A. Castro-Rodriguez et al.
PEDIATRIC PULMONOLOGY (2018)
Year in review 2017: Chronic obstructive pulmonary disease and asthma
Melissa J. Benton et al.
RESPIROLOGY (2018)
The Phosphodiesterase 4 Inhibitor Roflumilast Protects against Cigarette Smoke Extract-Induced Mitophagy-Dependent Cell Death in Epithelial Cells
Sun Young Kyung et al.
TUBERCULOSIS AND RESPIRATORY DISEASES (2018)
Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives
Panagiotis Paliogiannis et al.
EUROPEAN RESPIRATORY REVIEW (2018)
GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells
Taruna Joshi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Intolerance to roflumilast in real-life clinical practice
Monica Gomez-Rodriguez et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2017)
Dose dependent effects of tadalafil and roflumilast on ovalbumin-induced airway hyperresponsiveness in guinea pigs
Anna Urbanova et al.
EXPERIMENTAL LUNG RESEARCH (2017)
Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis
Masutaka Furue et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis
Alice C. Cheape et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue
Marco Spadaccini et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
2-Year animal carcinogenicity results for crisaborole, a novel phosphodiesterase 4 inhibitor for atopic dermatitis
Vic Ciaravino et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2017)
Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis
Lawrence F. Eichenfield et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Modulation of signaling through GPCR-cAMP-PKA pathways by PDE4 depends on stimulus intensity: Possible implications for the pathogenesis of acrodysostosis without hormone resistance
Emmanuelle Motte et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2017)
Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium
Joachim H. Ficker et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2017)
Addressing the Immunopathogenesis of Atopic Dermatitis: Advances in Topical and Systemic Treatment
Lawrence F. Eichenfield et al.
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY (2017)
Apremilast for the treatment of Behcet's syndrome
Gulen Hatemi et al.
EXPERT OPINION ON ORPHAN DRUGS (2017)
Pathological Roles of Neutrophil-Mediated Inflammation in Asthma and Its Potential for Therapy as a Target
Han Gao et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2017)
Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases
Theerasuk Kawamatawong
JOURNAL OF THORACIC DISEASE (2017)
Regulation of Inflammation, Its Resolution and Therapeutic Targeting
Mariagrazia Uguccioni et al.
FRONTIERS IN IMMUNOLOGY (2017)
Crisaborole: A new and effective nonsteroidal topical drug for atopic dermatitis
Ajay Kailas
DERMATOLOGIC THERAPY (2017)
Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives
Lazaros I. Sakkas et al.
CURRENT MEDICINAL CHEMISTRY (2017)
Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook
Jusleen Ahluwalia et al.
DRUGS (2017)
The isozyme selective phosphodiesterase-4 inhibitor, ABI-4, attenuates the effects of lipopolysaccharide in human cells and rodent models of peripheral and CNS inflammation
Joseph R. Hedde et al.
BRAIN BEHAVIOR AND IMMUNITY (2017)
Giemsa-stained pseudo-micronuclei in rat skin treated with vitamin D3 analog, pefcalcitol
Akira Takeiri et al.
GENES AND ENVIRONMENT (2017)
Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis
D. M. Paton
DRUGS OF TODAY (2017)
Asthma-COPD overlap syndrome-Coexistence of chronic obstructive pulmonary disease and asthma in elderly patients and parameters for their differentiation
Yoshihiro Tochino et al.
JOURNAL OF GENERAL AND FAMILY MEDICINE (2017)
Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis
Fuminori Ohba et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2016)
Cytokines in rheumatoid arthritis - shaping the immunological landscape
Iain B. McInnes et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled Study in Healthy Volunteers
Lee T. Zane et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2016)
Pharmacological Profile of GPD-1116, an Inhibitor of Phosphodiesterase 4
Takashi Nose et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2016)
In vivo effective dibenzo[b,d]furan-1-yl-thiazoles as novel PDE-4 inhibitors
Gopalan Balasubramanian et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex
Peter H. Schafer et al.
CELLULAR SIGNALLING (2016)
Effect of roflumilast on airway remodelling in a murine model of chronic asthma
S. W. Kim et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2016)
Chronic inflammatory airway diseases: the central role of the epithelium revisited
S. T. Gohy et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2016)
Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions
Naisargee Parikh et al.
CURRENT MEDICINAL CHEMISTRY (2016)
The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease
Mario Cazzola et al.
EXPERT OPINION ON DRUG DISCOVERY (2016)
Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis
Luca Bianchi et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis
Paola Rogliani et al.
EXPERT OPINION ON DRUG SAFETY (2016)
New therapeutic solutions for Behcet's syndrome
Antonio Vitale et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast
Andrea Chiricozzi et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2016)
PDE4B as a Microglia Target to Reduce Neuroinflammation
Damien D. Pearse et al.
GLIA (2016)
Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies
L. T. Zane et al.
IMMUNOTHERAPY (2016)
The phosphodiesterase 4 inhibitor roflumilast augments the Th17-promoting capability of dendritic cells by enhancing IL-23 production, and impairs their T cell stimulatory activity due to elevated IL-10
Matthias Bros et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2016)
Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study
Fuminori Ohba et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2016)
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design
Chimed Jansen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study
Jon M. Hanifin et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults
Amy S. Paller et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Advances in the treatment of cutaneous lupus erythematosus
A. Kuhn et al.
LUPUS (2016)
New insights into the immunopathogenesis of systemic lupus erythematosus
George C. Tsokos et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study
Lee T. Zane et al.
PEDIATRIC DERMATOLOGY (2016)
A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients
D. Singh et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2016)
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
Paolo Gisondi et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Psoriasis
Jacqueline E. Greb et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
The Regulation of NF-κB Subunits by Phosphorylation
Frank Christian et al.
CELLS (2016)
Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
Melinda Gooderham et al.
BIODRUGS (2015)
Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis
Hunar Abdulrahim et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner
Michael Lehrke et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2015)
Neuroinflammation in Alzheimer's disease
Michael T. Heneka et al.
LANCET NEUROLOGY (2015)
The psoriasis drugs market
Salman Rizvi et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Apremilast for Behcet's Syndrome - A Phase 2, Placebo-Controlled Study
Gulen Hatemi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Novel therapeutic targets in rheumatoid arthritis
Marije I. Koenders et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
CHF6001 II: A Novel Phosphodiesterase 4 Inhibitor, Suitable for Topical Pulmonary Administration-In Vivo Preclinical Pharmacology Profile Defines a Potent Anti-Inflammatory Compound with a Wide Therapeutic Window
Gino Villetti et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Stefan Siebert et al.
PHARMACOLOGICAL REVIEWS (2015)
CHF6001 I: A Novel Highly Potent and Selective Phosphodiesterase 4 Inhibitor with Robust Anti-Inflammatory Activity and Suitable for Topical Pulmonary Administration
Nadia Moretto et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis
Vlad Ratziu et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch- related responses in mice with chronic atopy-like dermatitis
Tsugunobu Andoh et al.
EXPERIMENTAL DERMATOLOGY (2014)
PDE inhibitors currently in early clinical trials for the treatment of asthma
Maria Gabriella Matera et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases
Ana Martinez et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2014)
Phosphodiesterase Inhibitors for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
Clive P. Page
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2014)
Effect of the phosphodiesterase 4 inhibitor E6005 on nerve growth factor elevation in irritated skin of NC/Nga mice
Naoto Ishii et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2014)
Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: Inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP
Tsugunobu Andoh et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2014)
Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: Results of a randomized, vehicle-controlled, multicenter clinical trial
Masutaka Furue et al.
JOURNAL OF DERMATOLOGY (2014)
Discovery and Early Clinical Development of 2-{6-[2-(3,5-Dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a Soft-Drug Inhibitor of Phosphodiesterase 4 for Topical Treatment of Atopic Dermatitis
Jakob Felding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Advances in targeting cyclic nucleotide phosphodiesterases
Donald H. Maurice et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
The PDE4 Inhibitor HT-0712 Improves Hippocampus-Dependent Memory in Aged Mice
Marco Peters et al.
NEUROPSYCHOPHARMACOLOGY (2014)
Atopic Dermatitis: Skin-Directed Management
Megha M. Tollefson et al.
PEDIATRICS (2014)
Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA-induced arthritis in rats
Diana A. Koch et al.
RHEUMATOLOGY (2014)
The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma
Brian R. Leaker et al.
BMC PULMONARY MEDICINE (2014)
Apremilast for the treatment of psoriatic arthritis
Sowmya Varada et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2014)
Targeting of interleukin-17 in the treatment of psoriasis
Ann Sophie Lonnberg et al.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2014)
The In Vitro Pharmacology of GS-5759, A Novel Bifunctional Phosphodiesterase 4 Inhibitor and Long Acting β2-Adrenoceptor Agonist
Stacey L. Tannheimer et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Clinical potential of apremilast in the treatment of psoriatic arthritis
Alberto Cauli et al.
IMMUNOTARGETS AND THERAPY (2014)
Roflumilast in the management of chronic obstructive pulmonary disease
Melissa Lipari et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2013)
Phosphodiesterase-4 Inhibitor Therapy for Lung Diseases
Bianca Beghe et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Phosphodiesterase 4-targeted treatments for autoimmune diseases
Neal Kumar et al.
BMC MEDICINE (2013)
NCS 613 exhibits anti-inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF-κB signalling pathways while reducing proinflammatory cytokine production
Issaka Yougbare et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2013)
Phosphodiesterase-4 inhibitors: a review of current developments (2010-2012)
Amadeu Gavalda et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2013)
Pipeline for COPD drugs flows with combination candidates
Helen Thompson
NATURE MEDICINE (2013)
Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD
Henrik Watz et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2013)
Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities
Ira Tabas et al.
SCIENCE (2013)
New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast
Andrew C. Palfreeman et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2013)
Antipruritic Effect of the Topical Phosphodiesterase 4 Inhibitor E6005 Ameliorates Skin Lesions in a Mouse Atopic Dermatitis Model
Naoto Ishii et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Exchange Protein Directly Activated by cAMP (epac): A Multidomain cAMP Mediator in the Regulation of Diverse Biological Functions
Martina Schmidt et al.
PHARMACOLOGICAL REVIEWS (2013)
Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease
Ana Garcia-Osta et al.
ACS CHEMICAL NEUROSCIENCE (2012)
Apremilast mechanism of action and application to psoriasis and psoriatic arthritis
Peter Schafer
BIOCHEMICAL PHARMACOLOGY (2012)
PDE4: A Novel Target in the Treatment of Chronic Obstructive Pulmonary Disease
J. M. Michalski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Tetomilast: new promise for phosphodiesterase-4 inhibitors?
Stephen J. Bickston et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Phosphodiesterase inhibitors in inflammatory bowel disease
Pooneh Salari et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor
Miki Kobayashi et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2012)
Disease Progression in MRL/lpr Lupus-Prone Mice Is Reduced by NCS 613, a Specific Cyclic Nucleotide Phosphodiesterase Type 4 (PDE4) Inhibitor
Therese Keravis et al.
PLOS ONE (2012)
NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues
Issaka Yougbare et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2011)
Phosphodiesterase 4 (PDE4) regulation of proinflammatory cytokine and chemokine release from rheumatoid synovial membrane
Anne Crilly et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity
Miki Kobayashi et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2011)
GSK256066, an Exceptionally High-Affinity and Selective Inhibitor of Phosphodiesterase 4 Suitable for Administration by Inhalation: In Vitro, Kinetic, and In Vivo Characterization
Cathy J. Tralau-Stewart et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
In Vivo Characterization of GSK256066, a High-Affinity Inhaled Phosphodiesterase 4 Inhibitor
Anthony T. Nials et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Anthranilic acid-based inhibitors of phosphodiesterase: Design, synthesis, and bioactive evaluation
Yih-Dih Cheng et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2011)
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment
Michel Gallant et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis
P. H. Schafer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety
Alex B. Burgin et al.
NATURE BIOTECHNOLOGY (2010)
Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis
Fiona E. McCann et al.
ARTHRITIS RESEARCH & THERAPY (2010)
The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma
Dave Singh et al.
RESPIRATORY RESEARCH (2010)
Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis
Tsutomu Akama et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury
J. Cortijo et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
PDE4 inhibitors: a review of current developments (2005-2009)
Lluis Pages et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2009)
CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease
J. N. Gordon et al.
JOURNAL OF CROHNS & COLITIS (2009)
Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor
Hon-Wah Man et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Effects of Roflumilast, a Phosphodiesterase-4 Inhibitor, on Hypoxia- and Monocrotaline-Induced Pulmonary Hypertension in Rats
Mohamed Izikki et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
Peter M. A. Calverley et al.
LANCET (2009)
Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides:: Identification of MK-0873, a potent and effective PDE4 inhibitor
Daniel Guay et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Tetomilast Suppressed Production of Proinflammatory Cytokines from Human Monocytes and Ameliorated Chronic Colitis in IL-10-Deficient Mice
Hitoshi Ichikawa et al.
INFLAMMATORY BOWEL DISEASES (2008)
MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers
J. D. Boot et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2008)
The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]
Victoria Boswell-Smith et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Efficacy and safety of roflumilast in the treatment of asthma
Eric D. Bateman et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2006)
Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis
S Videla et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
The inhibitory effects of roflumilast on lipopolysaccharide-induced nitric oxide production in RAW264.7 cells are mediated by heme oxygenase-1 and its product carbon monoxide
HJ Kwak et al.
INFLAMMATION RESEARCH (2005)
Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-κB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation
HJ Kwak et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Phosphodiesterase inhibitors for cognitive enhancement
GM Rose et al.
CURRENT PHARMACEUTICAL DESIGN (2005)
Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4)
JM O'Donnell et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2004)
Advances in immunology: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.
MD Kazatchkine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Atomic structure of PDE4: Insights into phosphodiesterase mechanism and specificity
RX Xu et al.
SCIENCE (2000)
Share Paper
